6 completed, 3 recruiting, 2 unknown, 1 active not recruiting. 12 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 6, Recruiting 3, Unknown 2, Active not recruiting 1 |
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow pretomanid: new trials by email Literature Review of pretomanid trials Research Report on pretomanid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis Bedaquiline, Quabodepistat, Pretomanid - Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis | Phase 3 | Recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 532 | 2025-10-16 | 2026-10-26 |
| Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis Bedaquiline, Linezolid, Pretomanid - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Recruiting | University of California, San Francisco | 400 | 2025-10-03 | 2026-09-02 |
| A PAN-USR TB Multi-Center Trial Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Recruiting | Shenzhen Third People's Hospital | 610 | 2025-06-18 | 2025-12-01 |
| A Pan-TB Regimen Targeting Host and Microbe Sutezolid, N-acetyl cysteine, Pretomanid - Tuberculosis | Phase 2 / Phase 3 | Active not recruiting | The Aurum Institute NPC | 352 | 2023-07-28 | 2025-05-28 |
| Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India Linezolid, Bedaquiline, Pretomanid - Pre-Extensively Drug-Resistant Pulmonary TB, Treatment Intolerant Multidrug-Resistant Pulmonary TB | Phase 3 | Unknown | Tuberculosis Research Centre, India | 400 | 2021-10-07 | 2024-01-03 |
| Economic Evaluation of New MDR TB Regimens Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | Medecins Sans Frontieres, Netherlands | 73 | 2020-10-20 | 2024-04-22 |
| PRACTECAL-PKPD Sub Study Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Unknown | Medecins Sans Frontieres, Netherlands | 240 | 2019-08-06 | 2021-05-14 |
| Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Pretomanid, Bedaquiline, Moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Completed | Global Alliance for TB Drug Development | 455 | 2018-07-30 | 2026-08-27 |
| Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis Pretomanid, Linezolid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 3 | Completed | Global Alliance for TB Drug Development | 181 | 2017-11-21 | 2023-06-29 |
| Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Bedaquiline, Pretomanid, Moxifloxacin - Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | Medecins Sans Frontieres, Netherlands | 552 | 2017-01-01 | 2024-05-01 |
| A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB Bedaquiline, PA-824, Linezolid - Pulmonary Tuberculosis | Phase 3 | Completed | Global Alliance for TB Drug Development | 109 | 2015-03-01 | 2025-09-08 |
| Shortening Treatment by Advancing Novel Drugs Moxifloxacin, PA-824, Pyrazinamide - Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant | Phase 3 | Completed | Global Alliance for TB Drug Development | 284 | 2015-02-01 | 2019-03-26 |
Tuberculosis, Multidrug-Resistant (9) · Tuberculosis, Pulmonary (8) · Tuberculosis (6) · Extensively Drug-Resistant Tuberculosis (5)
Global Alliance for TB Drug Development (4) · Medecins Sans Frontieres, Netherlands (3) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Shenzhen Third People's Hospital (1) · The Aurum Institute NPC (1) · Tuberculosis Research Centre, India (1) · University of California, San Francisco (1)
South Africa (9) · Georgia (4) · Belarus (3) · Philippines (3) · Tanzania (3) · Uganda (3) · China (2) · India (2) · Malaysia (2) · Moldova (2) · Peru (2) · Russia (2) · Uzbekistan (2) · Brazil (1) · Indonesia (1)
Bern Nyang'wa, MB BS, MPH (1) · Bern-Thomas Nyang'wa, MD (1) · Francesca Conradie (1) · Francesca Conradie, MD (1) · Morounfolu Olugbosi, MD (1) · Morounfolu Olugbosi, MD MSc (1) · Padmapriyadarsini Chandrasekharan (1) · Professor Robert Wallis, MD (1) · Sedona Sweeny (1) · Simbarashe G Takuva, MD, MSc. (1) · Stephen H Gillespie, MD (1)
PMID 36053506, PMID 36546625, PMID 37980911, PMID 26038418, PMID 26104205, PMID 32130813, PMID 34489274, PMID 34604901, PMID 35698158, PMID 36038181, PMID 36804834, PMID 36808186, PMID 37567554, PMID 38768617, PMID 38842323, PMID 41749341, PMID 41917253, PMID 42270675, PMID 42429813